{"name":"Affini-T Therapeutics, Inc.","slug":"affini-t-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"Affini-T Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for cancer. The company's lead candidate, AFNT-211, is currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AFNT-211","genericName":"AFNT-211","slug":"afnt-211","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AFNT-211","genericName":"AFNT-211","slug":"afnt-211","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFB1N2d4NnYwN0JiU181Tm9vV0dUM1c1NWVMUHNCdlZFVmRSZXpmRFp3TnBQUVJXYnFYV1VlNVBIZXU0TzY4bE5BNTd4NGpIT21aYlZHMy1qSW1HWDFH?oc=5","date":"2026-04-06","type":"pipeline","source":"BioSpace","summary":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees - BioSpace","headline":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQSDBXZ243SnRELU9tTG5VZTBBaUFIQkVwVmJEYW42OGc5emVxOWVhSGlZcng5U1RDZE5IWUM5YUdYRE1VSDBpVFZxTW5iNUF0X29DSUlDa3RBaHpKRmhwODNuU1hlRmEyQzNDLU9VUlVYN29vb3dTZFl1T21FU2FWNXpGZklzS2hZQXNoV21KczXSAZYBQVVfeXFMTmdVSG5xdU5Qa2JKdFpoQWYyaHhkUkxfM1FUdmljWjc5Z2VZYkxxRzhsa0VmZWZXc2h1UWY4MFFibXlwbXplT0VBS2dITk5ya1oxVlRwN3JJUF9fOFkwQlZ5eHB1NmNwRWZQV0NvMVlmSDZka3laZlZTMjNaN1FXdWxiU0hUSC1XckpWb09qRGNVSDI3UXdR?oc=5","date":"2026-01-17","type":"pipeline","source":"BioInformant","summary":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide - BioInformant","headline":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNUEtTenZlOHYzQnJTaTE3aHgyVzQzcmY0cVU5SnBPQnc5YzZYaXFOVTVlMjNCN1ZPeEN2dG92ZlM2d2d4dFphQ0xKNVRyOVNNTE5MS2ZHTy1xT3UwM09vUlNpQmRvT2ZXVEIzV0otNi10RVFqeTZsSXJSSHJwUTdyM3NNTWIwUDlsTXVfQlc0UQ?oc=5","date":"2026-01-06","type":"pipeline","source":"drugdiscoverytrends.com","summary":"50 cell and gene therapy leaders to watch in 2026 - drugdiscoverytrends.com","headline":"50 cell and gene therapy leaders to watch in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNeU5UQjJBMHkzTk40cHdEbTF1VkdoNnp3bTBZMlZiQVhVQ29USjNDQXBXckZFdUxfcVhFUHB1cHlyVjFPYnJyeVFUTDRubFRaVVdtbTBKdnZ4ZkNZUjNaRzdZbGROSzcxZGtaazJfejUwR3RGa3ZPQnkwRjFtTEFqUVRLaG8xcjY5S1E?oc=5","date":"2025-09-05","type":"pipeline","source":"Fierce Biotech","summary":"Merck KGaA lands new R&D chief—Chutes & Ladders - Fierce Biotech","headline":"Merck KGaA lands new R&D chief—Chutes & Ladders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOUGt6eTY0UkFGNk1ON01sVVUza1RxTDl4OGc0MXVtNUJfdXIwY0lqN1o2eDVSeFlLUnIxbTQtdW1SdnNqVHAtSkQtV3ZpWFloelFMWGJUendUQnFGVXhPNnV0U3p0eW9YUHFNXzhpcWVkcW01UWFRdmw3ZjkwVGZsR1JPYlNHMUN3TWNVSm9oTnFXR2VWcExtUm9Ra2tjSmsxU29NSGlwVEF0LW5MY1Vsaw?oc=5","date":"2025-07-24","type":"pipeline","source":"citybiz","summary":"T. Rowe Price, Catalio Capital Join $100 Million Series D for Avalyn Pharma - citybiz","headline":"T. Rowe Price, Catalio Capital Join $100 Million Series D for Avalyn Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPWC1uQ2lNQXFmb2trU2pVMkQtWW5RdkwtRzlEbFJ4Smx4VmhZNVpGbFdsdnBvMktRV2NTRmJNZngxRnlBR2tKY19nTDhMc2o1Z1NqS3hoZ2pDc0RQeG5FN1JST29CWlprQTIxUHRZSnBlWnJMRk1HZ0RrWHlFd0UzbDY2WnVjX1JsS2xiWG1SZGNIWW5Ob2VTeHh2M1c5elpuQWtzWThpcUwwT1ljS0pkMER5Q3liWWYwR2Fn?oc=5","date":"2025-07-01","type":"pipeline","source":"PharmTech.com","summary":"Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More - PharmTech.com","headline":"Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxPOC1xVGk2YkNGdHJPdXhJQUlsRjRZbDN6dDRiajl3blotREJVOUdfa1VQekxubnkxV3JvR0NObkJRQWllY2dPVlNQU2JqTVJsUVE4T1BGMkx1dGdmTFhDQ1ZQMGdIdTVob1hHYWpSN3FUdm11T3NhN3d6S05nR01pZzhZNTZ6RXBLdXVYa1N5MHgzRjAwcHBleFVWY2t4bHZvMlVjc2tybDZiellLVUt5dFd5bkVxVm90TmJKVks0d2JYcWM3dV83NHZwSGg5djVkLVpRNFppYU1adnVvYlUxcV9VUC1nUFo3Wk1wU1pITno?oc=5","date":"2024-04-08","type":"trial","source":"CRISPR Medicine News","summary":"Press Release Service: Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR) Annua","headline":"Press Release Service: Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOWURIRVQtamJCUDl6UFZFa3JCdmgxZEhxcVpZMjZ1ZTZWdlNheUV0QTlVNVJJMUNXcTV5VEJEM3B2bF9vRXduNHRBeDY0dW5mN0x1SVhfUnhfVE4xVWlZYkl0QTQ1d2p2QUdFT2htcE1Sd20zQnI5RUhwRGZLVldYUm1pNWFZam80aVc5cllOWmlzQ2VmMW52cnJIZTJaYWduZEE?oc=5","date":"2023-10-31","type":"trial","source":"Oncology Pipeline","summary":"Multi-specific antibodies and cell therapies enter phase 1 | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Multi-specific antibodies and cell therapies enter phase 1 | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxOZ0dFZG4xc0FHbk00ZE1mekpPd3pQWVpoRzVPLXhMSm1rNmdUVjhKcGdwWU54YUU1THlNUFRjVUtGN04yc285LURmbHkxbzE5MU40NFBxTDJvaVZ5YzdldGNtYWV0TWxDWE5WV1VLVWhOcXhDcjZjdVFfUFFnUE9tWWRCLUlsM1dUNFpmTkZrVmJkeTRJT3lYT282NVpPeUpXYmJRd2d4SjUxZ2RQT1VTcWs3SlNSWVdMSm9VMEl3Y3VIQUthUmt0eWl1ZWZ2a2x5M2MwQnM0eTY4Q2xUbnVrNXE2R3BTUkF3RmRTWGNWTFlVSXUzQ2FYbjIwMkQtZG5MaHFVNkdMbGlHN0dJaThQYk5WX2Njd1JvTEE?oc=5","date":"2022-06-15","type":"deal","source":"Business Wire","summary":"Affini-T Therapeutics & Metagenomi Announce Next-Generation Gene Editing Partnership to Advance Cell Therapies for Solid Tumor Patients - Business Wire","headline":"Affini-T Therapeutics & Metagenomi Announce Next-Generation Gene Editing Partnership to Advance Cell Therapies for Solid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPWWZ5bU5nVDdXRmtjQngtd1NmMW0yQmgtc09xTmdYUUZQQkhvQWR4R1JsZFNaVWE1d3ZhbEZIREdzVEgtekhIMHl5ZER3bFNYdGg4cWs2d3pJczBWbmtualZ5c0drMU5uSExQNVQ0b2tvTnluQUIyeG82Mk82Q1JCbEctamNoVW9hcVBwMzZmRDAza1JaeGw2aWdGSkc1LVdMNGlnakFsOTc?oc=5","date":"2022-03-22","type":"pipeline","source":"GeekWire","summary":"Fred Hutch spinout Affini-T Therapeutics lands $175M for cell therapies to treat solid tumors - GeekWire","headline":"Fred Hutch spinout Affini-T Therapeutics lands $175M for cell therapies to treat solid tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOY2Y5WFl0WmxUWjNackFyOGVhWnNVWWNLc2hvZ0h2SGdSb1kyS0pxdE1zMDRvSnBhZnVLNTB6S3g1dk15bHVpemJleWstX1RnY1NlYlZpVUpnTjNwdFdzcEJQZ2dKdGh5clBUVXR5QUVtUkdxalA3b3pqTVRoT21WOFBXRkdrdWw4dVd0N1VveDRDNUpUdndPMmE3Q0VlR3d3c2JIVl8yMkdBUE0?oc=5","date":"2022-03-22","type":"pipeline","source":"The Boston Globe","summary":"Affini-T Therapeutics launches with $175 million for cancer treatments - The Boston Globe","headline":"Affini-T Therapeutics launches with $175 million for cancer treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9YNWp1N2RwejZZU1dHUEpNTGp3VnJTaG16eWpEUlp1WWVSTkVDM2Q1OG9hNzl5TEluVTdJTmV1dTIweVNyV2NJN3NtanhWTF9vZUZjQU03S252ekZBdzFITGtCSHVhUlcxNGdxaW1ydkQ5c0VDTFVfWEVjYTR2ZGM?oc=5","date":"2022-01-13","type":"pipeline","source":"statnews.com","summary":"A new biotech startup looks to sidestep a key problem with CAR-T cancer therapies - statnews.com","headline":"A new biotech startup looks to sidestep a key problem with CAR-T cancer therapies","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}